Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer
Abstract Despite advances in its treatment, lung cancer still represents the most common and lethal tumor. Because of that, efforts to decipher the pathophysiological actors that may promote lung tumor generation/progression are being made, with the final aim of establishing new therapeutic options....
Guardado en:
Autores principales: | Adrián Sánchez-Fdez, María Florencia Re-Louhau, Pablo Rodríguez-Núñez, Dolores Ludeña, Sofía Matilla-Almazán, Atanasio Pandiella, Azucena Esparís-Ogando |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/86e191c9001f42a08729239785058682 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
por: Clara I Aceves-Luquero, et al.
Publicado: (2009) -
Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors
por: Pamela A. Lochhead, et al.
Publicado: (2020) -
The effect of arrestin conformation on the recruitment of c-Raf1, MEK1, and ERK1/2 activation.
por: Sergio Coffa, et al.
Publicado: (2011) -
K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling
por: Qing Yin, et al.
Publicado: (2019) -
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
por: Yu D, et al.
Publicado: (2021)